ArticleHaematologica2017

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Anna Vidal-Crespo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.